Documentos relacionados

1. A model of fracture risk used to examine the link between bone mineral density and the impact of different therapeutic mechanisms on fracture outcomes in patients with osteoporosis.
2. [Pharmacokinetics of selective estrogen receptor modulators(SERMs).]
3. Management of Osteoporosis in Chronic Kidney Disease.
4. Synthesis, preclinical, and pharmacokinetic evaluation of a new zoledronate derivative as a promising antiosteoporotic candidate using radiolabeling technique.
5. Basic research and clinical applications of bisphosphonates in bone disease: what have we learned over the last 40 years?
6. Bisphosphonates for treatment of osteoporosis: expected benefits, potential harms, and drug holidays.
7. A Phase IB multicentre dose-determination study of BHQ880 in combination with anti-myeloma therapy and zoledronic acid in patients with relapsed or refractory multiple myeloma and prior skeletal-related events.
8. Pharmacology of bisphosphonates.
9. Futility of current urine salbutamol doping control.
10. Pamidronate functionalized nanoconjugates for targeted therapy of focal skeletal malignant osteolysis.